Glover Rebecca E, Naylor Nichola R
Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK.
UK Health Security Agency, London NW9 5EQ, UK.
JAC Antimicrob Resist. 2023 May 25;5(3):dlad064. doi: 10.1093/jacamr/dlad064. eCollection 2023 Jun.
The development of national action plans (NAPs) for antimicrobial resistance (AMR) has been promoted and supported by the WHO, with recent support in the form of costing and budgeting tools to aid in finance-allocation decisions within governments.
In this brief report we review this WHO costing and budgeting tool, discuss the strengths and weaknesses, and consider its place alongside other health economics and policy-support tools developed.
We call for future analyses of the costs of AMR NAPs to consider costs beyond that of only implementation, through use of other available, open-access data and tools. These include the Global Antimicrobial Resistance and Use Surveillance System (GLASS) data and One Health tools already within the existing 'WHO toolbox'.
We suggest that future work on evaluating AMR along the impact pipeline use this toolbox where possible, ensuring empirical work is in turn open access.
世界卫生组织推动并支持制定抗微生物药物耐药性（AMR）国家行动计划（NAPs），近期还提供了成本核算和预算工具，以协助政府做出资金分配决策。
在本简要报告中，我们回顾了世界卫生组织的这一成本核算和预算工具，讨论其优缺点，并考量其在已开发的其他卫生经济学和政策支持工具中的地位。
我们呼吁未来对抗微生物药物耐药性国家行动计划的成本进行分析，通过使用其他可用的开放获取数据和工具，考虑除实施成本之外的其他成本。这些数据和工具包括全球抗微生物药物耐药性和使用监测系统（GLASS）的数据以及现有“世卫组织工具箱”中的“同一健康”工具。
我们建议，未来在沿着影响路径对抗微生物药物耐药性进行评估的工作中，尽可能使用这个工具箱，确保实证工作也能开放获取。
